Itinanggi ng pamunuan ng Pharmally Pharmaceutical Corporation na pinaboran ang kanilang kumpanya para makakuha ng kontrata sa gobyerno para sa COVID-19 medical supply.
Sa ikaapat na pagdinig ng Senate blue ribbon committee, sinabi ni Pharmally President Huang Tzu Yen na may pagkakataon din umano na madalas silang natatalo sa bidding.
“The allegations that the company is favored by the Procurement Entity. The company denies this. Pharmally Pharmaceutical is just like any business. Sometimes we win the business, and the customers purchase, sometimes they don’t and they go elsewhere,” sabi ni Huang sa kanyang opening statement.
“Pharmally Pharmaceutical does not always win. There have been 12 instances where the company bided, and we lost. These are all of public record. The company does not really have that 100% success story that some would want you to think,” dagdag pa nito.
Sa mga nasalihan umano nilang bidding, 52 porsiyent lang ang success rate ng kanilang kumpanya.
“The percentage of success bids to total number of bid attempts would indicate only a 52% success rate. While if you compare successful bid value, to the total value of all bids attempted, that percentage decreases to only 43%,” ayon kay Huang.
“What the data shows, is that the company just work really hard and try to be awarded while continues to successfully deliver on its obligations. There is absolutely no basis that this company can even be considered favored in any circumstances,” dagdag pa nito.
Iniimbestigahan ng Senate blue ribbon committee ang pagnili ng diumano’r overpriced na PPE na binili ng Procurement Service ng Department of Budget and Management (PS-DBM) sa ngalan ng Department of Health noong 2020.
Kinukuwestiyon ng mga senador ang Pharmally, isa sa mga supplier na nakakuha ng P8.6 bilyon halaga ng kontrata sa kabilang ng pagiging bago lang nito kumpanya na may kapital na P625,000 lamang.